Cargando…

1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities

BACKGROUND: UTIs are the most common infection after renal transplant (RTx) with an incidence of 6–86%. Post-RTx UTI has been associated with risk for graft loss and mortality, and RTx recipients are at risk for multidrug-resistant (MDR) UTI given immunosuppression (IS) and instrumentation. We sough...

Descripción completa

Detalles Bibliográficos
Autores principales: Bohn, Brian, Athans, Vasilios, Kovacs, Christopher, Stephany, Brian, Spinner, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253264/
http://dx.doi.org/10.1093/ofid/ofy210.1337
_version_ 1783373457966235648
author Bohn, Brian
Athans, Vasilios
Kovacs, Christopher
Stephany, Brian
Spinner, Michael
author_facet Bohn, Brian
Athans, Vasilios
Kovacs, Christopher
Stephany, Brian
Spinner, Michael
author_sort Bohn, Brian
collection PubMed
description BACKGROUND: UTIs are the most common infection after renal transplant (RTx) with an incidence of 6–86%. Post-RTx UTI has been associated with risk for graft loss and mortality, and RTx recipients are at risk for multidrug-resistant (MDR) UTI given immunosuppression (IS) and instrumentation. We sought to evaluate the incidence, timing, microbiology, and MDR risk of post-RTx UTI, as well as to characterize asymptomatic bacteriuria (ASB) practices at our center. METHODS: This was a retrospective cohort of subjects with ≥1 positive culture (≥10(5) CFU/mL) during the first year post-RTx that were transplanted from September 1, 2012 to October 1, 2016. Each bacteriuria episode was adjudicated as cystitis, pyelonephritis, or ASB (Figure 1). Subjects without bacteriuria were excluded from primary analysis but used to calculate UTI incidence. The primary outcome was 1-year symptomatic UTI incidence. Secondary outcomes: incidence of cystitis, pyelonephritis, and ASB; time-to-first UTI; microbiologic trends; and presence of MDR risk factors. RESULTS: Baseline characteristics: 52% male, median age 57 years, 65% stented, 34% antithymocyte globulin induction, 94% standard IS regimen (tacrolimus/mycophenolate/prednisone), 93% trimethoprim/sulfamethoxazole prophylaxis, and 21% receipt of IV antibiotics for ≥48 hours within 90 days of first positive culture (IV Abx); Of 527 RTx subjects, 100 had ≥1 positive culture. The 100 subjects had 234 cultures representing 359 isolates. Primary outcome: 12.1% symptomatic UTI incidence. Secondary outcomes (1-year incidences): 18.6% positive culture, 4.3% cystitis, 8.6% pyelonephritis, 11.9% ASB. Time to the first symptomatic UTI was a median of 50 days. A summary of microbiologic results can be found in Figure 2. ASB occurred 130 times and was treated 74.6% of the time (Figure 3). Significant risk factors for MDR UTI included female gender (P = 0.005), IV abx (P = 0.001), and recurrent UTI (P = 0.017). CONCLUSION: Incidence of symptomatic UTI at our center was lower than previous reports. E. coli and E. faecalis were the most common urinary pathogens identified. MDR risk factors identified were biologically plausible and consistent with prior literature. ASB treatment occurred frequently and is an area to target stewardship interventions. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253264
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62532642018-11-28 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities Bohn, Brian Athans, Vasilios Kovacs, Christopher Stephany, Brian Spinner, Michael Open Forum Infect Dis Abstracts BACKGROUND: UTIs are the most common infection after renal transplant (RTx) with an incidence of 6–86%. Post-RTx UTI has been associated with risk for graft loss and mortality, and RTx recipients are at risk for multidrug-resistant (MDR) UTI given immunosuppression (IS) and instrumentation. We sought to evaluate the incidence, timing, microbiology, and MDR risk of post-RTx UTI, as well as to characterize asymptomatic bacteriuria (ASB) practices at our center. METHODS: This was a retrospective cohort of subjects with ≥1 positive culture (≥10(5) CFU/mL) during the first year post-RTx that were transplanted from September 1, 2012 to October 1, 2016. Each bacteriuria episode was adjudicated as cystitis, pyelonephritis, or ASB (Figure 1). Subjects without bacteriuria were excluded from primary analysis but used to calculate UTI incidence. The primary outcome was 1-year symptomatic UTI incidence. Secondary outcomes: incidence of cystitis, pyelonephritis, and ASB; time-to-first UTI; microbiologic trends; and presence of MDR risk factors. RESULTS: Baseline characteristics: 52% male, median age 57 years, 65% stented, 34% antithymocyte globulin induction, 94% standard IS regimen (tacrolimus/mycophenolate/prednisone), 93% trimethoprim/sulfamethoxazole prophylaxis, and 21% receipt of IV antibiotics for ≥48 hours within 90 days of first positive culture (IV Abx); Of 527 RTx subjects, 100 had ≥1 positive culture. The 100 subjects had 234 cultures representing 359 isolates. Primary outcome: 12.1% symptomatic UTI incidence. Secondary outcomes (1-year incidences): 18.6% positive culture, 4.3% cystitis, 8.6% pyelonephritis, 11.9% ASB. Time to the first symptomatic UTI was a median of 50 days. A summary of microbiologic results can be found in Figure 2. ASB occurred 130 times and was treated 74.6% of the time (Figure 3). Significant risk factors for MDR UTI included female gender (P = 0.005), IV abx (P = 0.001), and recurrent UTI (P = 0.017). CONCLUSION: Incidence of symptomatic UTI at our center was lower than previous reports. E. coli and E. faecalis were the most common urinary pathogens identified. MDR risk factors identified were biologically plausible and consistent with prior literature. ASB treatment occurred frequently and is an area to target stewardship interventions. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253264/ http://dx.doi.org/10.1093/ofid/ofy210.1337 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Bohn, Brian
Athans, Vasilios
Kovacs, Christopher
Stephany, Brian
Spinner, Michael
1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities
title 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities
title_full 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities
title_fullStr 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities
title_full_unstemmed 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities
title_short 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities
title_sort 1508. urinary tract infections (utis) in the first year post-renal transplant: risks and opportunities
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253264/
http://dx.doi.org/10.1093/ofid/ofy210.1337
work_keys_str_mv AT bohnbrian 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities
AT athansvasilios 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities
AT kovacschristopher 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities
AT stephanybrian 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities
AT spinnermichael 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities